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Introduction
The incidence of colorectal cancer continues to increase.
In 2001 coleractal cancer was the second most common
malignancy in the Polish populace with 10 000 new cases
registered. Similar tendencies may be observed in other
developed countries [1, 2].
In Poland 5-year survival of patients with cancer of
the colon reaches 31.6%, while with cancer of the rectum
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I n t r o d u c t i o n.  Lymph node involvement is a very important prognostic factor in patients with colorectal cancer. The authors
have undertaken an attempt to identify the sentinel lymph node (SN) in this clinical entity in order to evaluate the role of this
method in defining disease advancement and its impact on treatment planning and prognosis
M a t e r i a l  a n d  m e t h o d s.  The study was performed on 41 pts with microscopically confirmed colorectal cancer. The
sentinel node was identified with dye in 41 pts, and immunohistochemically in 17 pts.
Re s u l t s.  The SN was identified in 95% of pts with cancer of the colon and in 62% of pts with cancer of the rectum. In 19 pts
we found no metastases in the SN nor in the other regional lymph nodes (RLN). In 3 pts the SN was the only node to contain
metastases. In 16 pts we found metastases both in the SN and in the RLN, while in 3 pts the SN contained no metastases while
they were present in other RLN.
S u m m a r y.  All pts underwent resection of the colon and of the regional lymph nodes. The query concerning the indications
for adjuvant chemotherapy in patients with confirmed micrometastases to the SN remains an open issue.
Zastosowanie techniki oznaczania w´z∏a „wartownika” w raku okr´˝nicy i odbytnicy
– doniesienie wst´pne
W s t ´ p.  Bardzo wa˝nym czynnikiem rokowniczym w raku jelita grubego jest obecnoÊç przerzutów nowotworowych w w´z∏ach
ch∏onnych. Autorzy podj´li prób´ zastosowania oznaczania w´z∏a „wartownika” (WW) w nowotworze o tej lokalizacji w celu
oceny przydatnoÊci omawianej metody w ustalaniu stopnia zaawansowania, wp∏ywu na planowane leczenie skojarzone
oraz rokowanie.
M a t e r i a ∏  i m e t o d a.  Badaniu poddano 41 pacjentów z rozpoznanym mikroskopowo rakiem jelita grubego. Do
oznaczenia w´z∏a wartownika zastosowano metod´ barwnikowà u 41 pacjentów oraz metod´ immunohistochemicznà
u 17 pacjentów.
W y n i k i.  W badanej grupie chorych w przypadku raka okr´˝nicy oznaczono WW u 95% badanych, zaÊ w raku odbytnicy
u 62% badanych. U 19 chorych nie stwierdzono przerzutów do WW, ani innych regionalnych w´z∏ów ch∏onnych (RWC). U 3
chorych WW by∏ jedynym w´z∏em zawierajàcym przerzuty. U 16 chorych stwierdzono przerzuty do WW i RWCU 3 pacjentów
stwierdzono przerzuty tylko do RWC przy braku przerzutów do WW.
Po d s u m o w a n i e.  Wszyscy pacjenci zostali poddani zabiegowi operacyjnemu, polegajàcemu na resekcji jelita i usuni´ciu
regionalnego uk∏adu ch∏onnego. Ustalenie wskazaƒ do chemioterapii uzupe∏niajàcej u pacjentów ze stwierdzonymi
mikroprzerzutami tylko do WW jest nadal sprawà otwartà.
S∏owa kluczowe: rak okr´˝nicy, rak odbytnicy, w´ze∏ ch∏onny „wartownik”
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– 28.6%. In the United States these values are better by
half – 59% and 57%, respectively [2].
Disease advancement is one of the most important
prognostic factors. The study which we have performed
was concerned with the identification and evaluation of
the sentinel lymph node (SN) and was aimed at resolving
the question whether immunohistochemical examination
will increase the number of recognized micrometastases,
and thus increase the number of indications for adjuvant
chemotherapy.
Material and methods
Between June 2002 and February 2004 we had attempted to
identify and analyze the sentinel lymph node in 41 patients with
colorectal cancer (25 pts with cancer of the colon and 16 pts
with cancer of the rectum) treated surgically at the Clinic of
Oncological Surgery of the Medical Academy in Gdaƒsk.
The patients entered the study only if the regional lymph
nodes were found not to be enlarged in USG and CT of the
abdomen and on macroscopic intraoperative evaluation. (TNM
advancement stage I and II).
Mean patient age was 67 yrs (range: 49-84 yrs). In all
patients with cancer of the colon we performed resection of the
colon together with the tumour and the regional lymph nodes
(right hemicolectomy in 6 cases, left hemicolectomy in 7 cases,
sigmoidectomy in 12 cases). Of the 16 pts with cancer of the
rectum 9 underwent rectal amputation (modo Miles) and 7 –
anterior resection (modo Dixon).
In order to identify the SN we applied the dye technique
described by Saha. In the case of cancers of the colon the dye
(1% methylene blue) was applied as a subserous injections, in
the case of cancer of the rectum – as a submucous injections, at
four points; 0.5 ml at each injection (Figure 1). The staining of
the lymphatic vessels and the lymph nodes was evaluated intra-
operatively – in case of cancers of the colon 10-15 minutes after
the application of the dye, while in case of cancers of the rectum
– directly after the resection of the mesorectum (Figure 2).
During pathological examination the nodes were dissected
every 100 µm and immunohistochemical (IHC) analysis was
performed. IHC analysis was performed in 17 cases – in patients
in whom the SN was found to contain no metastatic cells after
routine HE staining.
Results
We identified the SN in 24 pts (95%) with cancer of the
colon and in 10 pts (62%) with cancer of the rectum. In
3/41 pts the SN was the only lymph node containing
metastases. In 19/41 pts no metastases were found in both
the SN and in other regional lymph nodes (RLN). In
16/41 we found metastases in both the SN and RLN. In
3/41 pts only the RLN were found to contain metastases,
whereas there was no SN involvement. In one case (5.8%
of the entire group) IHC of the sentinel nodes revealed
the presence of isolated cancer cells.
Another issue was the evaluation of the influence
of disease advancement on the frequency of sentinel node
identification. In our material of patients with cancer of
the colon postoperative pTNM staging revealed 7 pts in
stage I, (altogether 14 SN examined), 9 pts in stage II
(altogether 11 SN examined) and 9 pts. in stage III
(altogether 11 SN examined).
In case of patients with cancer of the rectum we
found 12 pts in stage II (altogether 4 SN examined) and 4
pts. in stage III (altogether 2 nodes examined). There
were no stage I patients in the rectal cancer group.
Discussion
The analysis of the SN in patients with colorectal cancer is
still in the research stage [3]. Contrary to the treatment of
melanoma and breast cancer in patients with colorectal
cancer the identification of the sentinel lymph node does
not affect the span of the lymphadenectomy, but it
increases the frequency of identifying nodal metastases 
[4-13].
The first large report concerning the value of the
SN in colorectal cancer, basing upon a study of 203
patients, had been published by Saha in 1999 [10]. He
applied the staining technique, which allowed to identify
the sentinel node in 98% of patients. Conventional
pathological examination allowed to discern metastases in
36 patients (18%). A series of precise cuts of the SN
allowed to identify micrometastases in yet another 16
cases, while IHC analysis increased this number by yet
another 11 patients. This multicentered trial has shown
that the identification of the sentinel lymph node and its
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Figure 1. The technique of sentinel lymph node identification
in patients with cancer of the colon
Figure 2. The technique of sentinel lymph node
identification in patients with cancer of the rectum
careful evaluation changed the staging from I and II to III
acc. to AJCC in as many as 14% of patients. These 14%
of patients could greatly benefit from adjuvant chemo-
therapy [14].
Bilchik et al. performed an analysis of the SN in 100
patients with colorectal cancer. Once again they used the
staining method and identified the SN in 96% of cases.
A series of cuts and IHC analysis increased the number
of recognized metastases by 25 patients, i.e. stage of
advancement increased in case of 40% of patients [15].
Similar promising results have been reported by
Wood, who performed an analysis of 50 patients. The SN
was identified in 94% of cases; detailed analysis of the SN
verified the stage of advancement in 20% of cases, while
in 6% of cases the results were falsely negative [16]. The
same author applied the SN technique in the course of
laparoscopic excision of the colon. SN staining was
possible in the same percentage as in the case of classical
laparotomy, while detailed examination allowed to discern
micrometastases in 20% of patients [17-19].
According to Joosten et al. the concept of identifying
the SN with the aid of dye has no prognostic value. He
applied the technique in 35 cases and achieved false
negative results in the SN, with the presence of metastases
in other regional lymph nodes in 60% of cases [20].
In our material of 41 pts (25 with cancer of the colon
and 16 with cancer of the rectum) the SN was identified in
24 pts with cancer of the colon (95%) and in 10 pts with
cancer of the rectum (62%) [21]. In 17/41 pts in whom no
metastases were found in both the SN and the RLN
immunohistochemical methods have allowed to discern
the presence of isolated cancer cells in 5.8% of patients,
which allowed to change the staging from I and II to III.
The application of the SN technique is more
complex in the case of cancer of the rectum. In the study
reported by Bembenek et al. 48 patients had been
evaluated with a sensitivity of 70%, although the SN had
been identified in 96% of cases. In this study no
significant changes of the stage of clinical advancement
were observed [3].
Bilchik et al. have presented the results of the
evaluation of the SN with the aid of cytokeratin and PCR.
In his multicentered trial he evaluated the SN in 40
patients. In 53% of cases where, on classical examination,
the nodes were found to contain no metastases he
discerned micrometastases in the course of IHC analysis.
Thus, it was possible to identify a subgroup of patients at
greater risk of developing recurrence who could profit
from adjuvant chemotherapy [22, 23].
Broll et al. have presented the results of an analysis
of 49 pts with colorectal cancer. In patients initially
pronounced as stage I and II IHC has allowed to discern
micrometastases in as many as 26% of cases and in 33%
of these patients recurrence was observed. Among the
patients with no micrometastases recurrence was observed
only in 12% of cases. This study also proves that the
presence of micrometastases may, in fact, increase the
risk of recurrence, but the relatively small number of
enrolled patients does not allow for complete analysis
and further studies on larger patient groups are necessary
[24-28].
Our relatively small patient material does not allow
to draw any binding conclusions which could throw light
on this complex issue [21].
Tsavellas et al. have analyzed 9 publications con-
cerning the role of the SN in colorectal cancer. In 8 of
these reports identification was performed with the
staining technique. Only in one study did the authors
apply a combined dye-and-isotope technique. The num-
ber of patients in whom the evaluation of the SN altered
the advancement stage of the disease is reported to be
from 4 to 40%. The number of false negative results has
increased from none to 40%. In case of patients in whom
SN identification was performed with the aid of both dye
and radioisotope the ratio of false negative results was
20% [29].
Prabhadesai stresses the necessity for performing
further studies in order to evaluate the role of the SN in
colorectal cancer before introducing it into clinical
practice [30].
Yet another issue involved in the evaluation of the
SN in colorectal cancer is the identification of the SN in
the non-regional lymph nodes (the so-called “jumping
metastases”). According to different authors their
incidence varies from null to 7%, and in case of their
identification the extent of nodal dissection should be
increased [23].
Basing upon the analysis of literature reports one
may conclude that the identification of the sentinel lymph
node is relatively easy in patients with cancer of the colon,
whereas in case of cancers of the rectum the matter
becomes more difficult. Our study has provided similar
results, as we have managed to identify the SN in 95% of
patients with cancer of the colon and only in 62% of
patients with cancer of the rectum[21].
The influence of the presence of micrometastases
within the SN on patient prognosis is still the matter for
many discussions. Broll et al believe that the presence of
occult metastases discernible only immunohistochemically
may influence the frequency of local recurrence and
distant metastases and yet have no impact on the
prognosis concerning overall survival [25]. On the other
hand Nakanishi et al. believe that micrometastases have
no effect of patient prognosis [31] while Liefers et al.
have concluded that the presence of micrometastases
influences the length of survival of patients with colorectal
cancer [32].
Conclusions
The identification of the SN poses a problem in patients
with cancer of the rectum and demands further study in
order to evaluate the applicability of this method for the
diagnostics of regional lymph node metastases
In patients with cancer of the colon the number of
identified SN was higher in cases in a lesser stage of
advancement
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Attempts to evaluate the SN with immunohisto-
chemical techniques allow to discern isolated cancer cells
which could not be found with the aid of HE staining
There exists the necessity for long-term follow-up
of patients with confirmed micrometastases to sentinel
lymph nodes in order to evaluate the risk of their
developing recurrence and to assess their survival.
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